Navigation Links
Generex Provides Additional Details for October 21st Live Video Webcast
Date:10/20/2010

WORCESTER, Mass., Oct. 20 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) today announced additional details for its live video webcast scheduled for tomorrow, Thursday, October 21, 2010, in New York City.

Joining Mark Fletcher, the Company's Interim President & Chief Executive Officer, for the webcast will be:

  • Dr. Craig Eagle, a member of the Company's Scientific Advisory Board. Dr. Eagle currently serves as Vice-President of Strategic Alliances and Partnerships for the oncology business unit at Pfizer, Inc.
  • Dr. Jerry Bernstein, the Company's Vice-President for Medical Affairs.  Dr. Bernstein is a past President of the American Diabetes Association, an attending physician at Beth Israel Medical Centre, physician emeritus at Lenox Hill Hospital and Montefiore Medical Centre, both in New York City, and a member of the Board of Directors of the American Diabetes Association Research Foundation.
  • Dr. Joseph Rubinfeld, a member of the Company's Scientific Advisory Board (via telephone).  Dr. Rubinfeld is a founder of Amgen Inc. and SuperGen, Inc.
  • Dr. Eric von Hofe, President of the Company's wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc. (www.antigenexpress.com).
  • George Markus, Vice-President of Regulatory & Scientific Affairs.
  • Robert S. Shea, President & Chief Executive Officer of Global Medical Direct, LLC.
  • Dr. David Brusegard, a consultant to the Company in respect of the insurance and reimbursement and the integration of the Company and Global Medical Direct, LLC.

  • The particulars of the conference are as follows:Date:

    Thursday, October 21, 2010Time:

    1 p.m. EasternWhere:

    NASDAQ Marketsite, Times Square, 43rd & Broadway, NYCTo attend in-person, RSVP absolutely required for building security.  Please contact: bradley.smith@muncmedia.com Webcast:

    http://investor.generex.com/events.cfmSenior executives are available for media and analyst interviews prior and post the live event. Please contact Bradley Smith to schedule 917.680.6011 or bradley.smith@muncmedia.com

    About Generex Biotechnology Corporation Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's buccal insulin spray product, Generex Oral-lyn™, which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

    Safe Harbor Statement This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.  Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.  Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement.  No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.  Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials.  Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


    '/>"/>

    SOURCE Generex Biotechnology Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
    2. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
    3. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
    4. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
    5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
    6. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
    7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
    8. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
    9. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
    10. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
    11. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
    (Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
    (Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
    (Date:6/22/2016)... June 22, 2016  According to Kalorama Information, ... sequencing (NGS) market include significant efforts in automation ... More accessible and affordable sequencers, say the healthcare ... for consumables including sample prep materials.  The healthcare ... Sample Preparation for Next Generation Sequencing (NGS) , ...
    Breaking Biology Technology:
    (Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
    (Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
    (Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
    Breaking Biology News(10 mins):